Lucence received accreditation from the College of Pathologists (CAP) for our molecular diagnostics laboratory. This CAP accreditation recognizes Lucence for achieving the highest international laboratory standards for liquid biopsy testing.
This CAP accreditation adds to the international ISO 15189:2012 accreditation achieved by Lucence in 2017. The dual distinction underpins the company’s commitment to the highest global quality of cancer diagnostic services.
Dr. Tan Min-Han, CEO and Medical Director, said “We are very proud to achieve a dual CAP and ISO accreditation. This demonstrates that our molecular laboratory meets the most comprehensive quality standards for patient testing across the world. Maintaining high-level laboratory standards is important to ensure the accuracy of test results and patient diagnosis. This distinction is made possible because of the hard work and commitment that our team has put into achieving these stringent requirements for operational excellence.’’
The College of American Pathologists (CAP) is the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs. CAP’s mission is to ensure that there is excellence in how pathology and laboratory medicine is practiced around the world.
Lucence invents blood tests for faster, less invasive and more affordable cancer detection. The company’s flagship blood test LiquidHALLMARK® detects and monitors detects cancer-causing mutations and viruses in 14 different cancers. The test is based on its proprietary amplicon-based ultra-deep sequencing technology AmpliMARK™ for maximizing sensitivity, which is crucial for accurate detection and monitoring of cancer.